As per MRFR analysis, the India Biologics Market Size was estimated at 26.51 (USD Billion) in 2023. The India Biologics Market Industry is expected to grow from 30.81(USD Billion) in 2024 to 171.46 (USD Billion) by 2035. The India Biologics Market CAGR (growth rate) is expected to be around 16.888% during the forecast period (2025 - 2035).
The India Biologics Market is currently evolving owing to some key aspects. India’s increasing spending on health care coupled with growing cases of chronic disorders like cancer and diabetes is resulting in higher demand for biologic therapies. Also, government programs meant to develop the healthcare system further and ensure that advanced treatments are available to more people are enhancing the growth of this market. Investments in research and development in biotechnology by the public and private sectors are also significant to the growth of the market. Additionally, India’s market looks very promising in terms of prospects.
Domestic companies stand to benefit from the government’s support for local production of biologics to develop further and compete internationally. Better collaboration between universities and industries will enable them to create and market new biological products with enhanced features. Moreover, there is a need to pursue an interest in individualized medicine and biologics designed for specific patients. The general population is becoming more aware of the treatment options available, leading to a possibility in the market for innovative biologics that cater to specific health problems. Evolution in the country suggests that there is integration of technologies in the biologics development process.
The application of artificial intelligence and machine learning technologies is increasingly being adopted in drug discovery and development, making the processes more efficient and faster with regard to bringing biologics to market. Another trend that is likely to increase in India as more original biologics go off-patent is the shift towards biosimilars. This change could reduce expenses for patients and healthcare systems, enabling more widespread use of biologic therapies in the country. In general, the India Biologics Market is poised to expand tremendously due to these opportunities and trends.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders in India is a significant driver for the India Biologics Market Industry. According to the Indian Council of Medical Research, cancer cases in India are projected to rise by 27% by 2025, reaching approximately 1.5 million new cases annually. This surge in chronic diseases requires advanced treatment options such as biologics, which are effective in managing these conditions.
Leading organizations like the Serum Institute of India have already begun expanding their biologics portfolio to address the growing need for innovative therapies, contributing to market growth. Moreover, with the increasing healthcare expenditure by both the government and private sectors, there is a focus on developing new biologics, thereby propelling the market's expansion. Government initiatives, including the National Health Mission, aim to improve access to healthcare technologies, including biologics, further stimulating growth in this segment.
The substantial investment in research and development (R) within the Indian biopharmaceutical sector is driving the growth of the India Biologics Market Industry. The Indian government, along with private stakeholders, contributes significantly to R, with expenditure rising from USD 1.3 billion in 2020 to an anticipated USD 5 billion by 2025, according to the Department of Biotechnology. This funding enables the development of innovative biologics and biosimilars.
The presence of established companies like Biocon, which has been pivotal in biosimilar development, highlights the collaborative efforts between industry and academia that propel scientific advancements. Furthermore, initiatives like "Make in India" aim to position India as a global manufacturing hub for biologics, thereby enhancing research initiatives and attracting international partnerships.
India's evolving regulatory framework, particularly with respect to the approval process for biologics, acts as a catalyst for the growth of the India Biologics Market Industry. The Central Drugs Standard Control Organization has streamlined the biologics approval process, significantly reducing timeline hurdles. As of recent updates, the average time taken for biologics approval has decreased from 2-3 years to just around 6-12 months. This improvement encourages both domestic and international firms to invest in biologics development.
Companies like Dr. Reddy's Laboratories have successfully harnessed this regulatory support to expedite market entry for their biosimilars, enhancing competition and innovation in the industry.
The India Biologics Market is experiencing significant growth, especially in the Product Service segment, which encompasses a variety of therapeutic biologics. This segment comprises essential categories such as Monoclonal Antibodies, Interleukins, Vaccines, Growth Factors, Gene Therapy, and Others, each playing a crucial role in addressing major health issues indigenous to India.
Monoclonal Antibodies are particularly notable due to their targeted approach in treating diseases like cancer and autoimmune disorders, leading to increased preference among healthcare providers for precision therapies. Interleukins hold particular significance as they are pivotal in immune system modulation and treatment of diseases, including various forms of arthritis and cancers, contributing to the rising demand for immunotherapeutic options in the region.
Vaccines are a cornerstone of public health in India, reflecting the nation’s deep commitment to reducing the burden of communicable diseases. The recent advancements in vaccine technology, spurred by initiatives from the government and private sector collaboration, underscore the importance placed on immunization in improving health outcomes amongst the population. Growth Factors are gaining traction as well, particularly in regenerative medicine and tissue engineering, fostering innovations that contribute to wound healing and recovery from injuries.
Furthermore, Gene Therapy emerges as a transformative approach in the treatment of genetic disorders, offering hope to patients afflicted by conditions previously deemed untreatable while also aligning with India's push towards biotechnology advancement and agricultural applications. Each category within the Product Service segment holds unique attributes that cater to the specific needs of patients in India, highlighting the diverse capabilities of the biopharmaceutical industry in addressing health challenges.Overall, the interplay of these categories within the India Biologics Market emphasizes the segment's role in not only advancing healthcare but also providing economic opportunities alongside significant societal impact.
Continuous research and development in these areas are expected to fuel further innovations, ultimately enhancing the accessibility and effectiveness of biologics in the Indian healthcare system. Engaging in advanced biomanufacturing processes and leveraging local resources will enable India to establish itself as a leader in this burgeoning market, all while responding to the health demands of its vast population.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The India Biologics Market, particularly under the Disease Indication segment, reflects a profound transformation in the approach to treatment for various chronic and severe conditions. Rheumatoid arthritis, with its debilitating impacts, has driven a significant demand for biologics that target inflammatory pathways, providing relief and improving the quality of life for many patients. Similarly, psoriasis and psoriatic arthritis have seen a surge in novel biologic therapies that offer effective management, catering to the growing patient population in urban areas.
Cancer treatment through biologics stands as a crucial area, with advancements in monoclonal antibodies and immunotherapies reshaping oncology in India, thus enhancing survival rates. Diabetes, a prevalent health issue in the country, is increasingly being managed with innovative biologic insulin formulations, reflecting the shifting treatment paradigms. Additionally, the 'Others' category encompasses a range of conditions benefiting from the biologics arena, showcasing the diverse applications and growth possibilities in India. The market growth in this segment is driven by increasing health awareness, the expanding healthcare infrastructure, and the rising prevalence of these diseases, creating a favorable environment for the advancement of biological therapies.
The India Biologics Market has experienced significant growth driven by increasing investments in research and development, advancements in biotechnology, and rising demand for innovative therapies. This market is characterized by the presence of various key players and emerging companies that are actively involved in the development and commercialization of biologics, which include a range of products such as vaccines, monoclonal antibodies, and cell therapies.
The competitive landscape of this market is evolving rapidly with the entry of new players, collaborations, mergers, and acquisitions, enhancing the breadth of product offerings and expanding market reach. Companies are increasingly focusing on strategic partnerships and alliances to leverage technological advancements and improve their product pipelines, thereby intensifying competition for market share.
Johnson and Johnson India stands out in the India Biologics Market with a strong portfolio of biologic products, including vaccines and immunotherapies. The company leverages its extensive research and development capabilities to introduce innovative solutions that address critical public health needs. One of the key strengths of Johnson and Johnson India is its established reputation for quality and safety, which is paramount in the pharmaceutical and biotechnology sectors. The company also benefits from a robust distribution network that enhances its market presence across various regions in India, making its products readily available to healthcare providers and consumers.
Furthermore, Johnson and Johnson India has been able to maintain a leadership position through continuous investment in technology and strategic collaborations, positioning itself effectively in the competitive landscape of biologics.GSK India plays a pivotal role in the India Biologics Market by focusing on the development of vaccines and specialty biologics that cater to various diseases prevalent in the region. The company's portfolio includes both pediatric and adult vaccines, which are crucial in addressing public health challenges in the country. GSK India's strength lies in its strong commitment to research and development, allowing it to innovate and roll out high-quality biologics that meet the unique health needs of the Indian population.
Moreover, GSK India’s market presence is supported by its strategic partnerships and collaborations with local institutions, facilitating the expansion of its research capabilities and market reach. The company has also engaged in various mergers and acquisitions to bolster its biologics pipeline, thereby enhancing its competitive standing in the Indian market. Through these strategic initiatives, GSK India continues to establish itself as a key player in the biologics sector, providing innovative solutions to healthcare challenges faced in the country.
Recent developments in the India Biologics Market have shown significant growth and activity, particularly from key players such as Serum Institute of India, Biocon, and Bharat Biotech. The market has been buoyed by advancements in biopharmaceuticals and vaccinations, with the Serum Institute of India expanding its production capabilities to meet rising domestic and international demand. Biocon has also made strides, with its biologics portfolio receiving regulatory approvals for various treatments contributing to revenue growth. In December 2022, an acquisition was announced wherein Biocon acquired a biotechnology firm to enhance its research capabilities.
Moreover, collaboration between GSK India and local firms has ramped up, focusing on innovative research and product development. Notably, the Indian government has emphasized the importance of biotechnology, with initiatives launched to promote investment in the sector. The market's total valuation is expected to increase notably, with projections indicating a robust compound annual growth rate (CAGR) fueled by ongoing RD investments and the expansion of biosimilars and vaccines. Major companies like Pfizer India and AstraZeneca India are also expanding their product lines to capture market share, making the landscape dynamically competitive.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 26.51(USD Billion) |
| MARKET SIZE 2024 | 30.81(USD Billion) |
| MARKET SIZE 2035 | 171.46(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 16.888% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Johnson and Johnson India, GSK India, AbbVie India, AstraZeneca India, Sanofi India, Novartis India, Lupin Pharmaceuticals, Biocon, Pfizer India, Merck India, Mylan Laboratories, Serum Institute of India, Roche India, Zydus Cadila, Bharat Biotech |
| SEGMENTS COVERED | Product Service, Disease Indication |
| KEY MARKET OPPORTUNITIES | Increased investment in R&D, Growing demand for personalized medicine, Rise in chronic disease prevalence, Expanding biopharmaceutical manufacturing capabilities, Supportive government policies for biotech |
| KEY MARKET DYNAMICS | increasing chronic diseases prevalence, government support and funding, rapid technology advancements, growing biosimilars adoption, rising healthcare awareness and access |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Biologics Market is expected to be valued at 30.81 USD Billion in 2024.
By 2035, the India Biologics Market is projected to reach a value of 171.46 USD Billion.
The expected CAGR for the India Biologics Market from 2025 to 2035 is 16.888%.
By 2035, the monoclonal antibody segment is anticipated to dominate the market, valued at 55.0 USD Billion.
The vaccines segment is valued at 9.0 USD Billion in the India Biologics Market for the year 2024.
Major players in the India Biologics Market include Johnson and Johnson India, GSK India, and AbbVie India among others.
The interleukins segment is valued at 3.5 USD Billion in the year 2024.
By 2035, the gene therapy segment is projected to be valued at 26.46 USD Billion.
Challenges such as regulatory hurdles and high development costs may impact the growth of the India Biologics Market.
The growth factors segment is valued at 5.0 USD Billion in 2024, indicating significant investment in this area.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
